Published in Infect Dis Obstet Gynecol on January 01, 1999
Heat shock cognate protein 70 is involved in rotavirus cell entry. J Virol (2002) 1.37
Hyperthermia stimulates HIV-1 replication. PLoS Pathog (2012) 1.04
Hsp70 negatively controls rotavirus protein bioavailability in caco-2 cells infected by the rotavirus RF strain. J Virol (2006) 0.93
Anti-Vpr activity of a yeast chaperone protein. J Virol (2004) 0.86
HIV-1 viral protein R (Vpr) and its interactions with host cell. Curr HIV Res (2009) 0.81
HSP70 induced by Hantavirus infection interacts with viral nucleocapsid protein and its overexpression suppresses virus infection in Vero E6 cells. Am J Transl Res (2009) 0.80
An inducible heat shock protein 70 small molecule inhibitor demonstrates anti-dengue virus activity, validating Hsp70 as a host antiviral target. Antiviral Res (2016) 0.78
Cytokine analysis at the single cell level and lymphoproliferative responses to mycobacterial antigens in HIV-1 patients with successful virologic response to potent antiretrovirals. J Clin Immunol (2000) 0.75
Protein folding in the cell. Nature (1992) 19.60
A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell (1994) 8.52
Specific incorporation of cyclophilin A into HIV-1 virions. Nature (1994) 7.13
Functional association of cyclophilin A with HIV-1 virions. Nature (1994) 6.82
Cells in stress: transcriptional activation of heat shock genes. Science (1993) 4.83
Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell (1994) 4.50
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol (1996) 4.15
Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol (1991) 3.62
A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science (1995) 3.58
Heat shock proteins: molecular chaperones of protein biogenesis. Microbiol Rev (1993) 3.51
Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A (1986) 2.94
Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (1997) 2.92
Heat shock proteins and molecular chaperones: mediators of protein conformation and turnover in the cell. Cell (1994) 2.91
Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature (1991) 2.83
Progress in the development of an HIV-1 vaccine. Science (1998) 2.77
Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med (1997) 2.59
Functional specificity among Hsp70 molecular chaperones. Science (1997) 2.45
Human major histocompatibility complex contains genes for the major heat shock protein HSP70. Proc Natl Acad Sci U S A (1989) 2.34
A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer (1995) 2.12
Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol (1997) 1.98
Absconding with the chaperone: essential cyclophilin-Gag interaction in HIV-1 virions. Cell (1996) 1.94
Recognition of heat shock proteins and gamma delta cell function. Immunol Today (1990) 1.76
Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol (1998) 1.73
Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv Cancer Res (1993) 1.65
Localized or systemic in vivo heat inactivation of human immunodeficiency virus (HIV): a mathematical analysis. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.50
Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J Exp Med (1998) 1.50
Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci U S A (1997) 1.46
Calreticulin interacts with newly synthesized human immunodeficiency virus type 1 envelope glycoprotein, suggesting a chaperone function similar to that of calnexin. J Biol Chem (1996) 1.39
Protein folding and the regulation of signaling pathways. Cell (1994) 1.39
Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J Immunol (1996) 1.38
Definition of extracellular localized epitopes of Hsp70 involved in an NK immune response. Cell Stress Chaperones (1998) 1.36
Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes. J Exp Med (1994) 1.34
Analysis of the specificity and mechanism of transcriptional activation of the human hsp70 gene during infection by DNA viruses. J Virol (1991) 1.28
Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Proc Natl Acad Sci U S A (1996) 1.27
Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes. Proc Natl Acad Sci U S A (1998) 1.24
2-Cyclopenten-1-one, a new inducer of heat shock protein 70 with antiviral activity. J Biol Chem (1996) 1.19
Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods (1997) 1.18
Mechanistic independence of Nef and cyclophilin A enhancement of human immunodeficiency virus type 1 infectivity. Virology (1998) 1.17
CD3- large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72-kD heat shock protein on human sarcoma cells. Blood (1995) 1.13
Do heat shock proteins control the balance of T-cell regulation in inflammatory diseases? Immunol Today (1998) 1.12
Modulation of stress protein (hsp27 and hsp70) expression in CD4+ lymphocytic cells following acute infection with human immunodeficiency virus type-1. Virology (1997) 1.08
Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases. J Leukoc Biol (1989) 1.07
Heat shock induction of HIV production from chronically infected promonocytic and T cell lines. J Immunol (1990) 1.06
Heat-shock induction of the human immunodeficiency virus long terminal repeat. J Gen Virol (1988) 1.05
Heat shock proteins in immune response to cancer: the Fourth Paradigm. Experientia (1994) 1.04
Heat shock proteins and virus replication: hsp70s as mediators of the antiviral effects of prostaglandins. Experientia (1994) 1.04
Changes in natural immunity during the course of HIV-1 infection. Clin Exp Immunol (1993) 1.02
Inhibition of HIV-1 replication by cyclopentenone prostaglandins in acutely infected human cells. Evidence for a transcriptional block. J Clin Invest (1996) 0.99
Effects of dimethyl prostaglandin A1 on herpes simplex virus and human immunodeficiency virus replication. Antimicrob Agents Chemother (1992) 0.99
Surface expressed heat-shock proteins by stressed or human immunodeficiency virus (HIV)-infected lymphoid cells represent the target for antibody-dependent cellular cytotoxicity. Immunology (1992) 0.98
Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines. Semin Immunol (1997) 0.98
Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases. J Leukoc Biol (1991) 0.98
Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol Lett (1997) 0.97
Antigen presentation and related immunological aspects of HIV-1 vaccines. AIDS (1998) 0.91
Prostaglandin A inhibits replication of human immunodeficiency virus during acute infection. J Gen Virol (1991) 0.89
Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS. Clin Diagn Lab Immunol (1994) 0.88
An Hsp60 related protein is associated with purified HIV and SIV. J Med Primatol (1994) 0.88
The V3 loop of human immunodeficiency virus type-1 envelope protein is a high-affinity ligand for immunophilins present in human blood. Eur J Biochem (1998) 0.87
Heat shock proteins in immune responses. Crit Rev Immunol (1993) 0.86
Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders. AIDS (1990) 0.86
Colorectal cancer vaccines. Br J Surg (1998) 0.86
Viral infection. EXS (1996) 0.85
Immune responses to stress proteins: applications to infectious disease and cancer. Biotherapy (1998) 0.84
The kinetics of HIV-1 long terminal repeat transcriptional activation resemble those of hsp70 promoter in heat-shock treated HeLa cells. FEBS Lett (1994) 0.84
Heat shock proteins as immunological carriers and vaccines. EXS (1996) 0.84
Increased LAK activity against HIV-infected cell lines in HIV-1+ individuals. Clin Exp Immunol (1992) 0.83
Heat shock proteins and immunity. Res Immunol (1989) 0.83
Human immunodeficiency virus type 1 interaction with the membrane of CD4+ cells induces the synthesis and nuclear translocation of 70K heat shock protein. J Gen Virol (1994) 0.83
Molecular chaperones in the processing and presentation of antigen to helper T cells. Experientia (1994) 0.83
Altered constitutive and stress-regulated heat shock protein 27 expression in HIV type 1-infected cell lines. AIDS Res Hum Retroviruses (1995) 0.82
Selection of HTLV-I positive clones is prevented by prostaglandin A in infected cord blood cultures. Br J Cancer (1990) 0.81
Heat shock proteins as vaccine candidates. Semin Immunol (1991) 0.79
A critical contemplation on the role of heat shock proteins in transfer of antigenic peptides during antigen presentation. Behring Inst Mitt (1994) 0.78
Heat shock enhances the susceptibility of tumor cells to lysis by lymphokine-activated killer cells. Arch Otolaryngol Head Neck Surg (1995) 0.77
Chaperoning tumour antigens into the immune system. Lancet (1996) 0.76
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol (1992) 3.46
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 3.00
Role of Pr160gag-pol in mediating the selective incorporation of tRNA(Lys) into human immunodeficiency virus type 1 particles. J Virol (1994) 2.94
In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. J Virol (1992) 2.85
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1994) 2.81
Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother (1991) 2.40
Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication. J Virol (1994) 2.37
Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J Biol Chem (1994) 2.28
Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1. Virology (1993) 1.94
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 1.86
The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol (2000) 1.84
High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J Virol (1990) 1.83
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS (1998) 1.81
Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J Infect Dis (1990) 1.73
Mutations in the kissing-loop hairpin of human immunodeficiency virus type 1 reduce viral infectivity as well as genomic RNA packaging and dimerization. J Virol (1997) 1.68
AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells. Virology (1990) 1.64
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev (1995) 1.63
Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-plo incorporation into HIV-1. J Mol Biol (1997) 1.58
Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. Proc Natl Acad Sci U S A (1995) 1.56
HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Arch Biochem Biophys (1999) 1.55
Inhibition of gp160 and CD4 maturation in U937 cells after both defective and productive infections by human immunodeficiency virus type 1. J Virol (1991) 1.50
The role of Pr55(gag) in the annealing of tRNA3Lys to human immunodeficiency virus type 1 genomic RNA. J Virol (1999) 1.49
Incorporation of excess wild-type and mutant tRNA(3Lys) into human immunodeficiency virus type 1. J Virol (1994) 1.49
Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription. Adv Virus Res (1996) 1.48
The role of nucleocapsid and U5 stem/A-rich loop sequences in tRNA(3Lys) genomic placement and initiation of reverse transcription in human immunodeficiency virus type 1. J Virol (1998) 1.47
Effects of modifying the tRNA(3Lys) anticodon on the initiation of human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 1.42
Initiation of (-) strand DNA synthesis from tRNA(3Lys) on lentiviral RNAs: implications of specific HIV-1 RNA-tRNA(3Lys) interactions inhibiting primer utilization by retroviral reverse transcriptases. Proc Natl Acad Sci U S A (1996) 1.39
The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity. J Virol (1997) 1.37
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother (1995) 1.36
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses (1997) 1.36
Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis (2012) 1.36
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev (1995) 1.34
Variable tRNA content in HIV-1IIIB. Biochem Biophys Res Commun (1992) 1.34
Detection of human immunodeficiency virus type 1 (HIV-1) in genital ulcer exudate of HIV-1-infected men by culture and gene amplification. J Infect Dis (1990) 1.33
Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1. J Mol Biol (2000) 1.32
DNA found in human immunodeficiency virus type 1 particles may not be required for infectivity. J Gen Virol (1994) 1.32
Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC. J Gen Virol (1995) 1.31
Role of the mononuclear phagocyte system in the development of acquired immunodeficiency syndrome (AIDS). J Leukoc Biol (1988) 1.29
Temporal coordination between initiation of HIV (+)-strand DNA synthesis and primer removal. J Biol Chem (1999) 1.27
Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob Agents Chemother (1999) 1.26
Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase. Protein Expr Purif (1996) 1.25
Inducible expression of IkappaBalpha repressor mutants interferes with NF-kappaB activity and HIV-1 replication in Jurkat T cells. J Biol Chem (1998) 1.23
Infection of human monocytes/macrophages by HIV-1: effect on secretion of IL-1 activity. Immunology (1988) 1.22
Variant effects of non-native kissing-loop hairpin palindromes on HIV replication and HIV RNA dimerization: role of stem-loop B in HIV replication and HIV RNA dimerization. Biochemistry (1999) 1.21
Primer tRNA3Lys on the viral genome exists in unextended and two-base extended forms within mature human immunodeficiency virus type 1. J Virol (1997) 1.20
Effect of mutations in the nucleocapsid protein (NCp7) upon Pr160(gag-pol) and tRNA(Lys) incorporation into human immunodeficiency virus type 1. J Virol (1997) 1.19
Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris. Virology (1992) 1.18
Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1. J Virol (1996) 1.18
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother (1996) 1.16
The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase. J Biol Chem (1996) 1.16
Mechanisms of virus-induced immune suppression. Can Med Assoc J (1985) 1.14
Deletion mutagenesis within the dimerization initiation site of human immunodeficiency virus type 1 results in delayed processing of the p2 peptide from precursor proteins. J Virol (1999) 1.14
Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells. J Exp Med (1990) 1.13
In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Antiviral Res (1996) 1.12
Alcoholism and rapid progression to AIDS after seroconversion. Clin Infect Dis (1994) 1.12
Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. Antimicrob Agents Chemother (1999) 1.11
Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins. J Mol Biol (1998) 1.10
Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res (1997) 1.10
Cell-specific differences in activation of NF-kappa B regulatory elements of human immunodeficiency virus and beta interferon promoters by tumor necrosis factor. J Virol (1990) 1.10
Enhanced impairment of chain elongation by inhibitors of HIV reverse transcriptase in cell-free reactions yielding longer DNA products. Nucleic Acids Res (1998) 1.10
The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.09
Coordinate enhancement of cytokine gene expression in human immunodeficiency virus type 1-infected promonocytic cells. J Virol (1990) 1.09
Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Antimicrob Agents Chemother (1991) 1.09
Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother (1994) 1.09
Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol (2004) 1.09
Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1. J Virol (1999) 1.08
Cellular immunity against Rous sarcomas of chickens. Preferential reactivity against autochthonous target cells as determined by lymphocyte adherence and cytotoxicity tests in vitro. Proc Natl Acad Sci U S A (1974) 1.08
Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J Clin Microbiol (1994) 1.08
Monoclonal antibody-mediated inhibition of HIV-1 reverse transcriptase polymerase activity. Interaction with a possible deoxynucleoside triphosphate binding domain. J Biol Chem (1993) 1.07
Detection of unintegrated human immunodeficiency virus type 1 DNA in persistently infected CD8+ cells. J Gen Virol (1993) 1.07
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS (2001) 1.07
Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases. J Leukoc Biol (1989) 1.07
Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2003) 1.06
Why are there so many myths about AIDS? CMAJ (1993) 1.06
Roles of Pr55(gag) and NCp7 in tRNA(3)(Lys) genomic placement and the initiation step of reverse transcription in human immunodeficiency virus type 1. J Virol (2000) 1.06
Cell surface down-modulation of CD4 after infection by HIV-1. FASEB J (1994) 1.06
Viral inhibition of lymphocyte mitogenesis: interference with the synthesis of functionally active T cell growth factor (TCGF) activity and reversal of inhibition by the addition of same. J Immunol (1983) 1.05
Association of p56lck with the cytoplasmic domain of CD4 modulates HIV-1 expression. EMBO J (1994) 1.04
Stavudine resistance: an update on susceptibility following prolonged therapy. Antivir Ther (1999) 1.04
Role of distal zinc finger of nucleocapsid protein in genomic RNA dimerization of human immunodeficiency virus type 1; no role for the palindrome crowning the R-U5 hairpin. Virology (2001) 1.04
Human immunodeficiency virus, genital ulcers and the male foreskin: synergism in HIV-1 transmission. Scand J Infect Dis Suppl (1990) 1.04
Leader sequences downstream of the primer binding site are important for efficient replication of simian immunodeficiency virus. J Virol (2000) 1.04
The role of oxidative stress in disease progression in individuals infected by the human immunodeficiency virus. J Leukoc Biol (1992) 1.03
Changes in natural immunity during the course of HIV-1 infection. Clin Exp Immunol (1993) 1.02
Plasminogen activator is an apparent lymphocyte mitogen. J Immunol (1981) 1.01
Induction of monocytic differentiation and NF-kappa B-like activities by human immunodeficiency virus 1 infection of myelomonoblastic cells. J Exp Med (1992) 1.01
Sequence elements downstream of the human immunodeficiency virus type 1 long terminal repeat are required for efficient viral gene transcription. J Mol Biol (1997) 1.01
Role of stem B, loop B, and nucleotides next to the primer binding site and the kissing-loop domain in human immunodeficiency virus type 1 replication and genomic-RNA dimerization. J Virol (2001) 1.01
Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem (1995) 1.01